Stay updated on Ibrutinib Combo in Recurrent HNSCC Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib Combo in Recurrent HNSCC Clinical Trial page.

Latest updates to the Ibrutinib Combo in Recurrent HNSCC Clinical Trial page
- ChecktodayChange DetectedShow glossary is now enabled on the page, and the label for the updated QC metric has been changed to 'Last Update Submitted that Met QC Criteria'. The footer now includes 'No FEAR Act Data' and the page revision shows 'Revision: v3.4.0'.SummaryDifference0.2%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 on the page, indicating a small metadata update with no substantive changes to the study information.SummaryDifference0.1%

- Check36 days agoChange DetectedAdded a Locations section with California and updated the revision to v3.3.3; removed California Locations and HHS Vulnerability Disclosure.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page shows a revision update from v3.3.1 to v3.3.2; no changes to study details, eligibility criteria, or other core content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1 on the page. This appears to be an internal update with no changes to study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedThe site-wide notice regarding government funding and operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Ibrutinib Combo in Recurrent HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib Combo in Recurrent HNSCC Clinical Trial page.